{
    "nct_id": "NCT05515575",
    "official_title": "Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair",
    "inclusion_criteria": "* Age ≥ 18 years at the time of informed consent\n* Participants or their legally authorized representatives (LARs) need to be willing to provide written informed consent/assent for the trial\n* Be willing to comply with treatment protocol\n* Histologically confirmed unresectable or metastatic soft tissue or uterine sarcoma\n* Known deleterious or suspected deleterious alteration in at least one of the following prespecified DDR pathway genes:\n\nCore Genes\n\nGene Pathway\n\nBRCA1 FA/HR\n\nBRCA2 FA/HR\n\nBRIP1 FA/HR\n\nBARD1 FA/HR\n\nBLM FA/HR\n\nPALB2 FA\n\nMRE11 HR\n\nNBN HR\n\nRAD50 HR/NHEJ\n\nRAD51B FA/HR\n\nRAD51C HR\n\nRAD51D HR\n\nRAD52 HR\n\nRAD54B HR\n\nOther Genes\n\nGene Pathway\n\nABRAXAS1 NHEJ\n\nATM OTHER\n\nATR OTHER\n\nCHEK1 OTHER\n\nCHEK2 OTHER\n\nERCC4 NER\n\nERCC8 NER\n\nFANCA FA\n\nFANCC FA\n\nFANCD2 FA\n\nFANCE FA\n\nFANCF FA\n\nFANCG FA\n\nFANCI FA\n\nFANCL FA\n\nFANCM FA/HR\n\nMDC1 OTHER\n\nPARP1 BER\n\nRAD23B NER\n\nRECQL4 HR\n\nRPA1 NER\n\nSLX4 FA/HR\n\nXRCC2 FA/HR\n\nXRCC4 NHEJ\n\nXRCC6 NHEJ\n\nA= Fanconi Anemia BER = Base Excision Repair NER = Nucleotide Excision Repair HR = Homologous Recombination NHEJ = Non-homologous End Joining\n\n* Additional genes may be added to Appendix 18.1 in a study addendum as medical and scientific research and/or diagnostic testing evolves\n* Alterations of uncertain significance must be approved for inclusion by the Principal Investigator\n\n  * Performance status of ECOG ≤ 2\n  * Progressed on at least 1 prior line of systemic therapy.\n* Patients who decline standard of care first-line systemic therapy will be permitted to enroll\n* Prior adjuvant therapy will not count if it was completed more than 1 year before the date of consent\n\n  * Presence of measurable disease by RECIST 1.1\n* Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment.\n\n  * Adequate organ function determined within 14 days of treatment initiation, defined below:\n* Absolute neutrophil count (ANC) ≥ 1.5 K/mcL\n* Platelets ≥ 100 K/ mcL\n* Hemoglobin ≥ 9 g/dL\n* Serum creatinine OR Measured or calculated creatinine clearance Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 . For calculated CrCL, the Cockcroft Gault formula or institutional standard formula can be used.\n* Serum total bilirubin ≤1.5 X ULN OR ≤2 X ULN if hyperbilirubinemia is due to Gilbert's syndrome\n* AST (SGOT) and ALT (SGPT) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN\n* International Normalized Ratio ≤1.5 X ULN (≤ 2.5 × ULN if on anticoagulants)\n\n  * Women of childbearing potential must have a negative serum pregnancy test at screening and ≤ 72 hours prior to the first dose of study treatment.\n  * Women of childbearing potential must be willing to use a highly effective method of contraception and not breastfeed for the duration of the study and for at least 6 months after the last dose of study medication\n* Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\n  * Non-sterile male subjects and their female partners must be willing to use a highly effective method of contraception during the study treatment period and for at least 3 months after the last dose of study treatment. Nonsterile males must avoid sperm donation for the duration of the study and for at least 3 months after last study drug.\n  * Prior chemotherapy or any investigational therapies or other anti-cancer agent must have been completed at least 4 weeks before the study drug administration. All AEs must be ≤ NCI CTCAE v5 Grade 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline. Patients who were treated with estrogen modulating therapies (aromatase inhibitors, tamoxifen, GnRH agonists etc.) must have been treated at least 2 weeks prior to study drug administration.\n  * Radiation therapy encompassing >20% of the bone marrow is prohibited within 2 weeks prior to Day 1 and during study treatment. Note: Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment may be allowed.\n  * Patients must have normal blood pressure or adequately treated and controlled hypertension. (i.e. systolic BP ≤ 140 mmHg and diastolic BP ≤ 90 mmHg) .\n  * Patients receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy.\n  * Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.\n  * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with documented undetectable viral load and CD 4 count ≥350 within 6 months of the first dose of study treatment are eligible for this trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient is simultaneously enrolled on any therapeutic clinical trial.\n* Patient has had major surgery within 3 weeks prior to initiating protocol therapy. Note: patient must have recovered from any surgical effects.\n* Uncontrolled intercurrent illness including current active or chronic infection requiring systemic therapy or the following cardiac criteria:\n\n  * Symptomatic congestive heart failure (NYHA classification III or IV) within 6 months\n  * Acute myocardial infarction ≤6 months prior to Day 1\n  * Grade ≥2 ventricular arrhythmia ≤6 months prior to Day 1\n  * History of cerebrovascular accident within 6 months before first dose of study drugs\n* Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastases, or radiologic signs of CNS hemorrhage.\n\nNote: Participants with asymptomatic brain metastases (i.e. off corticosteroids and anticonvulsants for at least 7 days) are permitted.\n\n* Known history of active Mycobacterium tuberculosis infection\n* Prior therapy with a PARP inhibitor\n* Patients who have not recovered from clinically significant adverse events of prior therapy to ≤ NCI CTCAE v5 Grade 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline.\n\n  °If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy events due to a previously administered agent.\n* Presence of a gastrointestinal condition that may affect drug absorption\n* Known allergy or reaction to any component of the study drug or its excipients.\n* Women who are pregnant or breast feeding\n* Patients expecting to have a child within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of study treatment(s) for women or 7 months for men.\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Participant has received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy.\n* Participant has received colony stimulating factors (e.g., granulocyte colonystimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.\n\n  °If growth factors were used as neutropenic fever prophylaxis during a previous treatment regimen then enrollment is allowed, as long as 2 weeks as elapsed from the prior dose\n* Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.\n* Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n* Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).\n\n  * Patients with chronic HBV infection with active disease who are on suppressive antiviral therapy prior to initiation of cancer therapy\n  * Patients with HCV on treatment are eligible if HCV viral load is below the level of quantification",
    "miscellaneous_criteria": ""
}